356 related articles for article (PubMed ID: 30458922)
1. Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis.
Pepple KL; Lin P
Ophthalmology; 2018 Dec; 125(12):1977-1983. PubMed ID: 30458922
[TBL] [Abstract][Full Text] [Related]
2. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
Toussirot E
Inflamm Allergy Drug Targets; 2012 Apr; 11(2):159-68. PubMed ID: 22280236
[TBL] [Abstract][Full Text] [Related]
3. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis.
Yoshimura T; Sonoda KH; Ohguro N; Ohsugi Y; Ishibashi T; Cua DJ; Kobayashi T; Yoshida H; Yoshimura A
Rheumatology (Oxford); 2009 Apr; 48(4):347-54. PubMed ID: 19164426
[TBL] [Abstract][Full Text] [Related]
4. A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.
Verstockt B; Deleenheer B; Van Assche G; Vermeire S; Ferrante M
Expert Opin Drug Saf; 2017 Jul; 16(7):809-821. PubMed ID: 28573876
[TBL] [Abstract][Full Text] [Related]
5. Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.
Alunno A; Carubbi F; Cafaro G; Pucci G; Battista F; Bartoloni E; Giacomelli R; Schillaci G; Gerli R
Expert Opin Biol Ther; 2015; 15(12):1727-37. PubMed ID: 26653110
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
Thibodaux RJ; Triche MW; Espinoza LR
Expert Opin Biol Ther; 2018 Jul; 18(7):821-827. PubMed ID: 29949399
[TBL] [Abstract][Full Text] [Related]
7. Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer.
Quatresooz P; Hermanns-Lê T; Piérard GE; Humbert P; Delvenne P; Piérard-Franchimont C
J Biomed Biotechnol; 2012; 2012():147413. PubMed ID: 22754278
[TBL] [Abstract][Full Text] [Related]
8. Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.
Molinelli E; Campanati A; Brisigotti V; Offidani A
Curr Pharm Biotechnol; 2017; 18(12):964-978. PubMed ID: 29299984
[TBL] [Abstract][Full Text] [Related]
9. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
10. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.
Mugheddu C; Atzori L; Del Piano M; Lappi A; Pau M; Murgia S; Zucca I; Rongioletti F
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28833973
[TBL] [Abstract][Full Text] [Related]
11. IL-23: one cytokine in control of autoimmunity.
Croxford AL; Mair F; Becher B
Eur J Immunol; 2012 Sep; 42(9):2263-73. PubMed ID: 22949325
[TBL] [Abstract][Full Text] [Related]
12. Role of IL-17 and IL-22 in autoimmunity and cancer.
Blake SJ; Teng MW
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():41-50. PubMed ID: 25398491
[TBL] [Abstract][Full Text] [Related]
13. Roles of interleukin-17 in uveitis.
Guedes MC; Borrego LM; Proença RD
Indian J Ophthalmol; 2016 Sep; 64(9):628-634. PubMed ID: 27853008
[TBL] [Abstract][Full Text] [Related]
14. Responsiveness of Serum C-Reactive Protein, Interleukin-17A, and Interleukin-17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double-Blind, Placebo-Controlled Trials.
Siebert S; Sweet K; Dasgupta B; Campbell K; McInnes IB; Loza MJ
Arthritis Rheumatol; 2019 Oct; 71(10):1660-1669. PubMed ID: 31070869
[TBL] [Abstract][Full Text] [Related]
15. The role of Th17-associated cytokines in the pathogenesis of experimental autoimmune uveitis (EAU).
Sun D; Liang D; Kaplan HJ; Shao H
Cytokine; 2015 Jul; 74(1):76-80. PubMed ID: 25742774
[TBL] [Abstract][Full Text] [Related]
16. IL-23/IL-17 axis in the pathogenesis and treatment of systemic lupus erythematosus and rheumatoid arthritis.
Farah Izati A; Wong KK; Che Maraina CH
Malays J Pathol; 2020 Dec; 42(3):333-347. PubMed ID: 33361714
[TBL] [Abstract][Full Text] [Related]
17. The role of IL 23 in the treatment of psoriasis.
Puig L
Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
[TBL] [Abstract][Full Text] [Related]
18. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Kurzeja M; Rudnicka L; Olszewska M
Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
[TBL] [Abstract][Full Text] [Related]
19. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.
Verstockt B; Van Assche G; Vermeire S; Ferrante M
Expert Opin Biol Ther; 2017 Jan; 17(1):31-47. PubMed ID: 27817215
[TBL] [Abstract][Full Text] [Related]
20. Persistence of interleukin (IL)-17A+ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy.
Jack C; Mashiko S; Arbour N; Bissonnette R; Sarfati M
Br J Dermatol; 2017 Jul; 177(1):267-270. PubMed ID: 27599204
[No Abstract] [Full Text] [Related]
[Next] [New Search]
